Deverra Therapeutics

Seeking Remission For All

Print
Claim My Business
Form C
View on StartEngine
Min Investment
$500
Location
SEATTLE, WA
Expected Close Date
September 03, 2024
Target Raise
$15.00K-$1.24M
Security Price
$2.09
Website
deverratx.com
Number of Employees
12
Cash
$264,595
Revenue
$1,677,259
Short Term Debt
$7,222,643
Cost of Goods
$1,677,259
Long Term Debt
$0
Net Income
$1,672,096

Company Description

Deverra is a clinical-stage biotech company committed to providing universal donor treatments, opening doors for accessible & affordable immune cell therapies for cancer & other life-threatening illnesses.

Key Deal Facts

Deverra’s pioneering technology aims to reinvent the way immune cell therapies are developed & delivered. Our cell therapies are cost effective, safe & can be readily available – striving to make remission a reality for all patients.

Dilanubicel, Deverra’s lead clinical asset, has shown significantly improved remission rates in a phase 2 leukemia clinical trial with 184 patient infusions. Now, we’re just one clinical trial away from potential FDA approval.
Amount Raised : $975,776
Reveal the Score by Voting
＿
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
ⓘ
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
ⓘ
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
ⓘ
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
ⓘ
The value of the company compared to similar companies raising money from investors.
Valuation

Research Reports

No reports have been submitted

Become a Reporter
Read Our Research Disclaimer

0 Comments

Post Comment